Two-year regional grey and white matter volume changes with natalizumab and fingolimod
Article 2020 en
Authors
PP
Paolo Preziosa
MR
Maria A. Rocca
EP
Elisabetta Pagani
Abstract
1 min read
Natalizumab and fingolimod are associated with heterogeneous temporal and regional patterns of GM and WM atrophy progression. Compared with natalizumab, fingolimod-treated patients experience accelerated GM and WM atrophy in the cerebellum, while both drugs show minimal regional volumetric differences in supratentorial regions.
Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi
Discussion(0)
No comments yet. Be the first to comment.